Humanin vs SS-31
Both Humanin and SS-31 are used for mitochondrial and longevity. Here's how their evidence, dosing, and regulatory status actually compare.
Humanin
Evidence BHumanin (HN)
A 24-amino-acid mitochondrial-derived peptide with cytoprotective effects across Alzheimer's, diabetes, and atherosclerosis preclinical models. Endogenous levels decline sharply with age.
View full Humanin profile →SS-31
Evidence B+Elamipretide (SS-31)
A cell-permeable tetrapeptide that targets cardiolipin in the inner mitochondrial membrane. Investigated for primary mitochondrial myopathy, heart failure, and dry age-related macular degeneration.
View full SS-31 profile →Side-by-Side
| Attribute | Humanin | SS-31 |
|---|---|---|
| Evidence Grade | B | B+ |
| FDA Status | Not FDA-approved — mitochondrial-derived peptide research compound | Not FDA-approved — Phase 3 trials for primary mitochondrial myopathy |
| Typical Dose | Research range: 0.5–1 mg subcutaneous (rare clinical use) | Trial range: 40 mg subcutaneous daily |
| Clinics Indexed | 5 | 29 |
| Categories | mitochondrial, longevity, neuroprotection | mitochondrial, longevity |
Key reported benefits — Humanin
- ✓Cytoprotection
- ✓Anti-amyloid effects
- ✓Insulin sensitization
Key reported benefits — SS-31
- ✓Mitochondrial cardiolipin support
- ✓ATP production
- ✓Reduced oxidative damage
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.